CX 717

Drug Profile

CX 717

Alternative Names: Ampakine® CX717; CX717

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer Cortex Pharmaceuticals; National Institute on Drug Abuse; RespireRx Pharmaceuticals
  • Class Antidementias
  • Mechanism of Action AMPA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Spinal cord injuries
  • Preclinical Drug abuse
  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Respiratory insufficiency; Sleep disorders

Most Recent Events

  • 14 Jun 2017 Phase-I clinical trials in Spinal cord injuries (unspecified route) before June 2017 (RespireRx Pipeline, June 2017)
  • 14 Jun 2017 RespireRx plans to file an IND, and initiate a phase II trial investigating the ability of CX 717 to improve breathing in patients with spinal cord injury, during 2017
  • 19 Jan 2016 RespireRx Pharmaceuticals and NIDA agree to co-develop CX 717 in USA for Drug abuse
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top